Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05718531
Other study ID # Anti-Thrombotics CAE
Secondary ID
Status Not yet recruiting
Phase Phase 3
First received
Last updated
Start date February 1, 2023
Est. completion date August 2025

Study information

Verified date January 2023
Source Assiut University
Contact Hamed M. Abdelhafez, Master
Phone +201016604262
Email hamed.m.h.abdelhafez@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

1. To evaluate short and intermediate clinical outcome of different anti-thrombotic regimens on major adverse cardiac events (MACE) and quality of life in coronary artery ectasia patients. 2. To evaluate role of P-selectin as a marker of cardiovascular risk in coronary artery ectasia.


Description:

Coronary artery ectasia (CAE) is the diffuse dilatation of coronary artery. It is defined as a dilatation with a diameter of 1.5 times the adjacent normal coronary artery . Its prevalence ranges from 1.2%-4.9% with male to female ratio of 3:1. CAE is more common in males. Hypertension is a risk Factor. Interestingly, patients with Diabetes Mellitus (DM) have low incidence of CAE. This may be due to down regulation of matrix metalloproteinase (MMP) with negative re-modelling in response to atherosclerosis. Smoking appears to be more common in patients with CAE than in those with coronary artery disease (CAD). Treatment for CAE is a controversial topic, as there is lack of clinical trials and standardized guidelines, Current options include: 1. aggressive risk-factor modification 2. Management of the coronary artery disease if obstructive lesions are found. Anti-platelet therapy with aspirin has been suggested for all CAE patients since most have coexistent coronary artery obstructive lesions and high likelihood of developing a myocardial infarction (MI). There have not been any prospective random studies evaluating the role of adenosine diphosphate inhibitors as part of therapy. Considering anticoagulation therapy to prevent coronary thrombus formation has been a debatable topic due to limited randomized trials.it was strongly suggested to use warfarin as the basic treatment for achieving long-term anticoagulation in one study. Efficacy and safety of novel oral anti-coagulants (NOACs) are superior to warfarin in patients with non-valvular atrial fibrillation, By searching the literature, there are few cases of the application of NOACs in coronary ectasia. Rivaroxaban has been showed to reduce ischemic events and cardiovascular mortality along with a higher risk for bleeding in Subjects with Acute Coronary Syndrome (ACS) suggested by the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 trial on a background of clopidogrel treatment.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 200
Est. completion date August 2025
Est. primary completion date February 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - all patients diagnosed with coronary artery ectasia either associated with obstructive or non-obstructive coronary artery disease after undergoing coronary angiography at cath. lab, cardiology department, Assiut university heart hospital, Assiut university. Exclusion Criteria: 1. Atrial fibrillation 2. Left ventricular thrombus 3. severe Valvular heart disease. 4. Mechanical valve prothesis 5. Crusade score = 41 (high - very high risk) 6. deep venous thrombosis, pulmonary embolism 7. renal failure stage IV-V. 8. known malignancy 9. Evidence of acute or chronic infection (by history or clinical examination). 10. History of systemic inflammatory or autoimmune disease. 11. History of any clinically significant endocrine, hematologic, respiratory, or metabolic diseases

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Rivaroxaban 2.5 Mg Oral Tablet twice daily
effect of rivaroxaban 2.5 mg twice daily on MACE and quality of life in coronary artery ectasia patients.
Clopidogrel 75 Mg Oral Tablet
Used as control group in 2nd arm and 5th arm
Aspirin tablet 75 mg
Used as control group in 2nd arm and 5th arm

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

References & Publications (6)

Doi T, Kataoka Y, Noguchi T, Shibata T, Nakashima T, Kawakami S, Nakao K, Fujino M, Nagai T, Kanaya T, Tahara Y, Asaumi Y, Tsuda E, Nakai M, Nishimura K, Anzai T, Kusano K, Shimokawa H, Goto Y, Yasuda S. Coronary Artery Ectasia Predicts Future Cardiac Events in Patients With Acute Myocardial Infarction. Arterioscler Thromb Vasc Biol. 2017 Dec;37(12):2350-2355. doi: 10.1161/ATVBAHA.117.309683. Epub 2017 Oct 19. — View Citation

Khedr A, Neupane B, Proskuriakova E, Jada K, Kakieu Djossi S, Mostafa JA. Pharmacologic Management of Coronary Artery Ectasia. Cureus. 2021 Sep 8;13(9):e17832. doi: 10.7759/cureus.17832. eCollection 2021 Sep. — View Citation

Oldridge N, Hofer S, McGee H, Conroy R, Doyle F, Saner H; (for the HeartQoL Project Investigators). The HeartQoL: Part I. Development of a new core health-related quality of life questionnaire for patients with ischemic heart disease. Eur J Prev Cardiol. 2014 Jan;21(1):90-7. doi: 10.1177/2047487312450544. Epub 2012 Jul 20. — View Citation

Oldridge N, Hofer S, McGee H, Conroy R, Doyle F, Saner H; (for the HeartQoL Project Investigators). The HeartQoL: part II. Validation of a new core health-related quality of life questionnaire for patients with ischemic heart disease. Eur J Prev Cardiol. 2014 Jan;21(1):98-106. doi: 10.1177/2047487312450545. Epub 2012 Jul 20. — View Citation

Pranata R, Yonas E, Chintya V, Alkatiri AA. Is Anticoagulant Necessary in Patients with Coronary Artery Ectasia Presenting with Acute Coronary Syndrome? A Systematic Review of Case Reports. Int J Angiol. 2019 Dec;28(4):231-236. doi: 10.1055/s-0039-1692706. Epub 2019 Jun 28. — View Citation

Ramappa P, Kottam A, Kuivanemi H, Thatai D. Coronary artery ectasia--is it time for a reappraisal? Clin Cardiol. 2007 May;30(5):214-7. doi: 10.1002/clc.20002. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Major adverse cardiac events Major adverse cardiac events occurence 1 year
Primary P selectin marker Correlation of P selectin marker with the severity of the disease. 1 year
Secondary Bleeding risk Bleeding events occurence 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT05233124 - Antithrombotic Therapy in Acute Coronary Syndromes and Coronary Artery Ectasia Phase 2
Recruiting NCT05713201 - Outcomes After PCI of the Aneurysmatic Right Coronary Artery
Recruiting NCT04265989 - A New Classification and Interventional Therapy for Coronary Artery Ectasia N/A
Recruiting NCT00548457 - Endothelial Function in Patients With Ectatic Compared to Normal Coronary Arteries N/A
Completed NCT02024919 - Effect of Diltiazem on Coronary Artery Ectasia N/A
Not yet recruiting NCT05213429 - Jordanian Coronary Artery Ectasia Registry
Completed NCT05410678 - Safety And Efficacy Results of Percutaneous Renal Stent Implantation in Ectatic and Aneurysmatic Coronary Arteries Phase 4
Recruiting NCT02831153 - Evaluation of Emotional Status and Coronary Flow Characteristics by TIMI Frame Count Method N/A
Recruiting NCT02818127 - Assessment Of Total Coronary Circulation Time Using TIMI Frame Count Method (TCCT-TIMI) N/A
Recruiting NCT06057987 - Coronary Artery Ectasia Database - Poland
Not yet recruiting NCT05692115 - Ischemia and Inflammatory Markers Among Patients With Coronary Artery Ectasia
Recruiting NCT05106530 - Arrhythmogenic Risk Assessment in Coronary Artery Ectasia Patients
Completed NCT06220682 - Endothelial NO Synthase Polymorphic Gene in Coronary Artery Dilation Disease